Visum Therapeutics Company
Visum Therapeutics develops small molecule y p p g therapeutic to treat Stargardt's disease, a degenerative condition that leads to blindness and is the most common form of inherited juvenile macular degeneration. Much of the pathology of Stargardt's disease is shared with the more common Age-related Macular Degeneration (AMD).
Technology:
P4 Medicine
Industry:
Biotechnology, Health Diagnostics, Life Science, Therapeutics
Headquarters:
Cleveland, Ohio, United States
Founded Date:
1-1
Funding Status:
Seed
Register and Claim Ownership